Despite missing statistical significance, Grail said the observation of trending improvement suggests potential for better results with more time, so the company is extending follow up by up to a year. More detailed trial results will be submitted for presentation at the annual meeting of the American Society of Clinical Oncology.
The post Grail’s Galleri Blood Test Falls Short in Large Cancer-Screening Study, Shares Sink 50% appeared first on MedCity News.
